Novo Nordisk Raises 2026 Outlook as Obesity Sales Jump 22%
Novo Nordisk lifts its 2026 outlook after Q3 sales reach DKK79.20 billion and obesity revenue rises 22% at constant exchange rates, despite impairments.
Explore MarketSpeaker's latest reporting, research, and expert analysis tagged with "novo nordisk", collected in one continuously updated archive.
Novo Nordisk lifts its 2026 outlook after Q3 sales reach DKK79.20 billion and obesity revenue rises 22% at constant exchange rates, despite impairments.
Novo Nordisk is partnering with Anthropic to deploy Claude Science and frontier AI models across drug discovery and software development as the pharmaceutical giant seeks to accelerate the creation of new medicines.
Novo Nordisk has partnered with OpenAI to enhance its drug discovery efforts using advanced AI tools, aiming to accelerate identification of new treatments.